Bristol Myers Squibb now offers the first FDA-approved treatment option for the prevention of acute graft versus host disease in patients 2 years of age and older undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor.

Amadou Diarra, senior vice president, Global Policies and Government Affairs, discusses his Mobile Mission in the latest installment of the Black Organization for Leadership and Development (BOLD) Innovators podcast series.

Tomorrow's Innovators is an initiative that builds a sustainable bridge for diverse talent from Historically Black Colleges and Universities (HBCUs) to the biopharma industry.